*Refers to actual RITUXAN HYCELA injection time of 5 or 7 minutes and does not account for all aspects of treatment. Actual clinic time may vary.
†The PrefMab Trial, studied in previously untreated DLBCL and follicular lymphoma, demonstrated that 77% of patients preferred subcutaneous administration of RITUXAN HYCELA vs rituximab IV after Cycle 8 (n=620) as it required less time in clinic.
The BrandX™ Co-pay Card Program may help lower the out-of-pocket costs for your patients.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.